Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.

Autor: Amin A; Levine Cancer Institute, Charlotte, NC USA., Dudek AZ; University of Illinois Cancer Center, Chicago, IL USA., Logan TF; Indiana University Simon Cancer Center, Indianapolis, IN USA., Lance RS; Urology of Virginia, Norfolk, VA USA., Holzbeierlein JM; University of Kansas Medical Center, Kansas City, KS USA., Knox JJ; Princess Margaret Hospital, Toronto, ON Canada., Master VA; Emory University, Atlanta, GA USA., Pal SK; City of Hope Comprehensive Cancer Center, Duarte, CA USA., Miller WH Jr; Lady Davis Institute and Segal Cancer Center-Jewish General Hospital, McGill University, Montreal, QC Canada., Karsh LI; The Urology Center of Colorado, Denver, CO USA., Tcherepanova IY; Argos Therapeutics, Inc., Durham, NC USA., DeBenedette MA; Argos Therapeutics, Inc., Durham, NC USA., Williams WL; Argos Therapeutics, Inc., Durham, NC USA., Plessinger DC; Argos Therapeutics, Inc., Durham, NC USA., Nicolette CA; Argos Therapeutics, Inc., Durham, NC USA., Figlin RA; Cedars-Sinai Medical Center, Los Angeles, CA USA.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2015 Apr 21; Vol. 3, pp. 14. Date of Electronic Publication: 2015 Apr 21 (Print Publication: 2015).